EA200300982A1 - Гетероциклические производные для лечения рака и других пролиферативных заболеваний - Google Patents

Гетероциклические производные для лечения рака и других пролиферативных заболеваний

Info

Publication number
EA200300982A1
EA200300982A1 EA200300982A EA200300982A EA200300982A1 EA 200300982 A1 EA200300982 A1 EA 200300982A1 EA 200300982 A EA200300982 A EA 200300982A EA 200300982 A EA200300982 A EA 200300982A EA 200300982 A1 EA200300982 A1 EA 200300982A1
Authority
EA
Eurasian Patent Office
Prior art keywords
substituted
aryl
heteroaryl
alkyl
cancer
Prior art date
Application number
EA200300982A
Other languages
English (en)
Russian (ru)
Inventor
Магнус Пфаль
Хуссейн А. Аль-Шамма
Андреа Фанджул
Дэвид П. М. Плейнет
Лайл В. Спрюс
Торстен Р. Вайманн
Джейсон Б. Ибарра
Кэтрин Тачджиан
Original Assignee
Инсайт Сан Диего, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Инсайт Сан Диего, Инк. filed Critical Инсайт Сан Диего, Инк.
Publication of EA200300982A1 publication Critical patent/EA200300982A1/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D277/00Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
EA200300982A 2001-03-07 2002-03-07 Гетероциклические производные для лечения рака и других пролиферативных заболеваний EA200300982A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27475101P 2001-03-07 2001-03-07
PCT/US2002/007001 WO2002072009A2 (en) 2001-03-07 2002-03-07 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases

Publications (1)

Publication Number Publication Date
EA200300982A1 true EA200300982A1 (ru) 2004-12-30

Family

ID=23049469

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300982A EA200300982A1 (ru) 2001-03-07 2002-03-07 Гетероциклические производные для лечения рака и других пролиферативных заболеваний

Country Status (12)

Country Link
US (1) US7153875B2 (enExample)
EP (1) EP1385465A4 (enExample)
JP (1) JP2005506290A (enExample)
AU (1) AU2002252227A1 (enExample)
BR (1) BR0207846A (enExample)
CA (1) CA2440184A1 (enExample)
EA (1) EA200300982A1 (enExample)
IL (1) IL157740A0 (enExample)
MX (1) MXPA03008117A (enExample)
NO (1) NO20033883L (enExample)
PL (1) PL373912A1 (enExample)
WO (1) WO2002072009A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515003B1 (en) 1999-08-31 2003-02-04 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of diabetes and other diseases
PL373912A1 (en) 2001-03-07 2005-09-19 Incyte San Diego, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
WO2002072543A2 (en) 2001-03-08 2002-09-19 Maxia Pharmaceuticals, Inc. Rxr activating molecules
US20030083357A1 (en) * 2001-08-17 2003-05-01 Magnus Pfahl Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
WO2003043998A1 (en) * 2001-11-15 2003-05-30 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
EP1456165A1 (en) 2001-11-30 2004-09-15 The Burnham Institute Induction of apoptosis in cancer cells
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) * 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
EP1606285A4 (en) * 2003-03-27 2009-03-18 Lankenau Inst Medical Res NEW IDO HEMMER AND APPLICATION PROCEDURES
FR2856401B1 (fr) * 2003-06-20 2010-02-12 Galderma Res & Dev Nouveaux composes modulateurs des recepteurs de type ppargamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
DE10351744A1 (de) * 2003-10-31 2005-06-16 Schering Ag Thiazolidinone, deren Herstellung und Verwendung als Arzneimittel
US7122700B2 (en) 2004-07-30 2006-10-17 Xerox Corporation Arylamine processes
AU2006233810B2 (en) * 2005-04-08 2011-02-17 Galderma Research & Development New method for the preparation of 6-(3-(1-adamantyl)-4-methoxphenyl)-2-naphthoic acid
FR2884248B1 (fr) * 2005-04-08 2007-05-18 Galderma Res & Dev Nouveau procede de preparation de l'acide 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphtoique
KR100814109B1 (ko) * 2006-01-09 2008-03-14 한국생명공학연구원 로다닌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 약학적 조성물
CL2007000995A1 (es) * 2006-04-11 2008-06-27 Smithkline Beecham Corp Compuestos derivados de tiazolidinadiona; composicion farmaceutica; y uso para tratar uno o mas estados de enfermedad seleccionada entre trastornos autoinmunes, enfermedad inflamatoria, cardiovascular y neurodegenerativa entre otras.
US20080255115A1 (en) * 2007-04-11 2008-10-16 Michael Gerard Darcy Thiazolidinedione derivatives as pi3 kinase inhibitors
US7592342B2 (en) * 2007-05-10 2009-09-22 Smithkline Beecham Corporation Quinoxaline derivatives as PI3 kinase inhibitors
PE20090717A1 (es) 2007-05-18 2009-07-18 Smithkline Beecham Corp Derivados de quinolina como inhibidores de la pi3 quinasa
JP2011505341A (ja) * 2007-11-21 2011-02-24 デコード ジェネティクス イーエイチエフ 炎症性、心血管およびcns障害を治療するビアリールpde4抑制剤
WO2009067621A1 (en) 2007-11-21 2009-05-28 Decode Genetics Ehf Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
CN102558088A (zh) * 2010-12-31 2012-07-11 中国科学院上海药物研究所 联苯亚甲基-2-硫代-4-噻唑酮类化合物及其制备方法和用途
US20250066347A1 (en) * 2021-12-21 2025-02-27 Medific, Inc. Substituted thiazolidinedione derivative compound, and pharmaceutical composition for preventing or treating cancer, comprising same
US12115148B1 (en) 2024-05-10 2024-10-15 Imam Mohammad Ibn Saud Islamic University 3-(2-(1,3-dioxoisoindolin-2-yl)ethyl)-5-(2-hydroxy-5-nitrobenzylidene)thiazolidine-2,4-dione as a potential antitumor and apoptotic inducer

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4051842A (en) 1975-09-15 1977-10-04 International Medical Corporation Electrode and interfacing pad for electrical physiological systems
DE2626348C3 (de) 1976-06-11 1980-01-31 Siemens Ag, 1000 Berlin Und 8000 Muenchen Implantierbare Dosiereinrichtung
JPS5538359A (en) 1978-09-12 1980-03-17 Hamari Yakuhin Kogyo Kk Preparation of 2-(3-benzoylphenyl)-propionic acid
US4383529A (en) 1980-11-03 1983-05-17 Wescor, Inc. Iontophoretic electrode device, method and gel insert
IL72684A (en) 1984-08-14 1989-02-28 Israel State Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs
US4931279A (en) 1985-08-16 1990-06-05 Bausch & Lomb Incorporated Sustained release formulation containing an ion-exchange resin
US4713244A (en) 1985-08-16 1987-12-15 Bausch & Lomb Incorporated Sustained-release formulation containing an amino acid polymer with a lower alkyl (C1 -C4) polar solvent
US4668506A (en) 1985-08-16 1987-05-26 Bausch & Lomb Incorporated Sustained-release formulation containing and amino acid polymer
CA1325222C (en) 1985-08-23 1993-12-14 Lederle (Japan), Ltd. Process for producing 4-biphenylylacetic acid
DE3874257T2 (de) 1987-03-11 1993-02-11 Kanegafuchi Chemical Ind Hydroxystyren-derivate.
FI91869C (fi) * 1987-03-18 1994-08-25 Tanabe Seiyaku Co Menetelmä antidiabeettisena aineena käytettävien bensoksatsolijohdannaisten valmistamiseksi
US5223522A (en) 1988-03-08 1993-06-29 Pfizer Inc. Thiazolidinedione hypoglycemic agents
US5330998A (en) 1988-03-08 1994-07-19 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
IE940525L (en) 1988-05-25 1989-11-25 Warner Lambert Co Known and selected novel arylmethylenyl derivatives of¹thiazolidinones, imidazolidinones and oxazolidinones useful¹as antiallergy agents and antiinflammatory agents
FI940306A0 (fi) 1991-07-22 1994-01-21 Pfizer Menetelmä kiraalisten tiatsolidiini-2,4-dionijohdannaisten synteesissä tarvittavien välituotteiden valmistamiseksi
US5780676A (en) 1992-04-22 1998-07-14 Ligand Pharmaceuticals Incorporated Compounds having selective activity for Retinoid X Receptors, and means for modulation of processes mediated by Retinoid X Receptors
ATE195716T1 (de) 1992-04-22 2000-09-15 Ligand Pharm Inc Retinoid-x rezeptor selektive verbindungen
EP0915090A1 (en) 1992-09-10 1999-05-12 Eli Lilly And Company Compounds useful as hypoglycemic agents and for treating Alzheimer's disease
EP0671005A1 (en) 1992-11-25 1995-09-13 La Jolla Cancer Research Foundation Rxr homodimer formation and bridged bicyclic aromatic compounds and their use in modulating gene expression
MX9603414A (es) 1994-02-17 1997-03-29 American Home Prod Derivados de bifenilo sustituidos como inhibidores de fosfodiesterasa.
US5691376A (en) 1994-02-17 1997-11-25 American Home Products Corporation Substituted biphenyl derivatives
JPH09136877A (ja) 1995-06-16 1997-05-27 Takeda Chem Ind Ltd 複素環化合物、その製造法及び用途
AU701790B2 (en) 1995-07-17 1999-02-04 Centre International De Recherches Dermatologiques Galderma (C.I.R.D. Galderma) Method for treating cancers using 6-{3-{1-adamantyl}- 4-hydroxyphenyl}
CN1196730A (zh) 1996-06-19 1998-10-21 雷迪博士研究基金会 具有增强的抗糖尿病活性的穴糖酮的新的多晶型形式及其制备方法
CZ3499A3 (cs) 1996-07-08 1999-11-17 Galderma Research & Development, S. N. C. Adamantylová sloučenina, její použití a farmaceutický prostředek ji obsahující
EP1007038A2 (en) 1997-08-21 2000-06-14 Takeda Chemical Industries, Ltd. Anti-inflammatory agent
US5972986A (en) 1997-10-14 1999-10-26 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
AU1052599A (en) 1997-11-12 1999-05-31 Institute Of Medicinal Molecular Design. Inc. Retinoid receptor agonists
US6262044B1 (en) 1998-03-12 2001-07-17 Novo Nordisk A/S Modulators of protein tyrosine phosphatases (PTPASES)
US6331633B1 (en) 1998-05-08 2001-12-18 Calyx Therapeutics Inc. Heterocyclic analogs of diphenylethylene compounds
KR20010099623A (ko) 1998-08-21 2001-11-09 비로파마 인코포레이티드 바이러스 감염 및 관련 질병을 치료 또는 예방하는화합물, 조성물 및 방법
AU6330999A (en) 1998-09-30 2000-04-17 Roche Diagnostics Gmbh Rhodanine derivatives for the treatment and prevention of metabolic bone disorders
WO2000032598A1 (en) 1998-12-04 2000-06-08 Structural Bioinformatics Inc. Methods and compositions for treating inflammatory diseases utilizing inhibitors of tumor necrosis factor activity
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
US6462032B1 (en) 1999-05-04 2002-10-08 Wyeth Cyclic regimens utilizing indoline derivatives
US6515003B1 (en) * 1999-08-31 2003-02-04 Maxia Pharmaceuticals, Inc. Heterocyclic derivatives for the treatment of diabetes and other diseases
KR100608416B1 (ko) 1999-11-12 2006-08-02 후지모토 쿄다이 가부시키가이샤 2-(n-시아노이미노)티아졸리딘-4-온 유도체
FR2812876B1 (fr) 2000-08-08 2002-09-27 Galderma Res & Dev Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques
PL373912A1 (en) 2001-03-07 2005-09-19 Incyte San Diego, Inc. Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
WO2002072543A2 (en) 2001-03-08 2002-09-19 Maxia Pharmaceuticals, Inc. Rxr activating molecules
EP1373240B1 (en) 2001-03-14 2005-06-15 Eli Lilly And Company Retinoid x receptor modulators
WO2002080935A1 (en) 2001-04-04 2002-10-17 Ortho Mcneil Pharmaceutical, Inc. Combination therapy comprising glucose reabsorption inhibitors and retinoid-x receptor modulators
US20030083357A1 (en) 2001-08-17 2003-05-01 Magnus Pfahl Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia
WO2003043998A1 (en) 2001-11-15 2003-05-30 Incyte San Diego Incorporated N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders, cancer, and other diseases
AR037714A1 (es) 2001-12-06 2004-12-01 Maxia Pharmaceuticals Inc Derivados de tiazolidinona y oxazolidinona 2-sustituidos para la inhibicion de fosfatasas y el tratamiento de cancer
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US7102000B2 (en) 2002-03-08 2006-09-05 Incyte San Diego Inc. Heterocyclic amide derivatives for the treatment of diabetes and other diseases
CA2529154C (en) * 2003-06-20 2013-05-07 Galderma Research & Development, S.N.C. Novel compounds that modulate ppar.gamma. type receptors, and use thereof in cosmetic or pharmaceutical compositions

Also Published As

Publication number Publication date
US20020143182A1 (en) 2002-10-03
CA2440184A1 (en) 2002-09-19
JP2005506290A (ja) 2005-03-03
US7153875B2 (en) 2006-12-26
NO20033883L (no) 2003-11-05
EP1385465A4 (en) 2005-09-07
BR0207846A (pt) 2005-09-13
PL373912A1 (en) 2005-09-19
IL157740A0 (en) 2004-03-28
EP1385465A2 (en) 2004-02-04
NO20033883D0 (no) 2003-09-02
AU2002252227A1 (en) 2002-09-24
MXPA03008117A (es) 2004-11-12
WO2002072009A3 (en) 2003-10-16
WO2002072009A2 (en) 2002-09-19

Similar Documents

Publication Publication Date Title
EA200300982A1 (ru) Гетероциклические производные для лечения рака и других пролиферативных заболеваний
DE60226912D1 (de) Chinolin- und Chianzolinderivate zur Behandlung von Tumoren
DE69830504D1 (de) Antithrombotische mitteln
MEP61208A (en) Novel compounds having inhibitory activity against sodium-dependant transporter
AP1753A (en) Thiophene derivatives as antiviral agents for flavvivirus infection
NO913750L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater.
WO2001019828A3 (en) Kinase inhibitors as therapeutic agents
DE60107449D1 (de) Substituierte aminopropoxyarylderivate als lxr agonisten
AU7517400A (en) N-substituted 4-aminopteridines, synthesis and use thereof as pharmaceutical agent
MY138263A (en) Therapeutic chroman compounds
ID24846A (id) Turunan-turunan bifenilamidina
ATE272617T1 (de) Sulfonamid-derivate
DE60330758D1 (de) Bestimmte pharmazeutisch wertvolle substituierte aminoalkyl-heterocyclen
EA200500095A1 (ru) Производные 4-(7-гало-2-хино(кса-)линилокси)феноксипропионовой кислоты в качестве противоопухолевых средств
DE60002558D1 (de) Derivate der Phosphonsäure zur Inhibierung von Carboxypeptidase B
EA200401099A1 (ru) Производные гетероциклического амида
AU2002214320A1 (en) Imidazole derivatives, process for their preparation and their use
NO20033049D0 (no) Fremgangsmåte for fremstilling av (+/-) trans-4-p-fluorfenyl- 3-hydroksymetyl-1
EA200101050A1 (ru) Замещенные бензолактамные соединения
SE0103646D0 (sv) Therapeutic chroman compounds
TR200001161A2 (tr) 8-Siklopentil-6-etil-3-[ikame edilmiş]-5, 8-Dihidro-4H-1, 2, 3A, 7, 8-Pentaaza-As-Indasenlerin hazırlandığı işlem ve burada yararlı ara bağlar.
EA200200462A1 (ru) Производные 2-арилхинолина, их получение и терапевтическое применение